Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) EBT: 2020-2023

Historic EBT for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$15.5 million.

  • Immuneering's EBT fell 15.44% to -$15.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$54.8 million, marking a year-over-year decrease of 8.03%. This contributed to the annual value of -$54.8 million for FY2023, which is 8.50% down from last year.
  • As of Q4 2023, Immuneering's EBT stood at -$15.5 million, which was down 18.95% from -$13.1 million recorded in Q3 2023.
  • In the past 5 years, Immuneering's EBT registered a high of -$3.2 million during Q2 2020, and its lowest value of -$15.5 million during Q4 2023.
  • Its 3-year average for EBT is -$11.6 million, with a median of -$12.6 million in 2022.
  • Data for Immuneering's EBT shows a maximum YoY crashed of 149.56% (in 2021) over the last 5 years.
  • Immuneering's EBT (Quarterly) stood at -$5.8 million in 2020, then crashed by 88.02% to -$11.0 million in 2021, then fell by 22.75% to -$13.5 million in 2022, then declined by 15.44% to -$15.5 million in 2023.
  • Its EBT was -$15.5 million in Q4 2023, compared to -$13.1 million in Q3 2023 and -$12.3 million in Q2 2023.